We're celebrating the American Glaucoma Society's 40th Anniversary! Dr. Emily Schehlein interviews three glaucoma luminaries, previous AGS Presidents, and guest editors for Ophthalmology Glaucoma's AGS 40th Anniversary special issue: Dr. Steven Gedde, Dr. Carla Siegfried, and Dr. Greg Skuta. Together they discuss the past, present, and future of the AGS, advancements in the treatment of glaucoma, and share their personal stories of mentorship and community within the society.

Read Ophthalmology Glaucoma's American Glaucoma Society 40th Anniversary supplement issue here:

https://www.ophthalmologyglaucoma.org/issue/S2589-4196(25)X0006-5

To find out more about the AGS, how to join, and get involved visit:

https://www.americanglaucomasociety.net/home

Sign up for the next Ophthalmology Journal Virtual Club on February 25, 2026, at https://store.aao.org/ophthalmology-virtual-journal-club.html

It's our 100th episode! Dr. Rukhsana Mirza sits down with Drs. Aleksandra V. Rachitskaya and Kevin C. Allan to discuss their retrospective study using the TriNetX network to investigate the risk of neovascular age-related macular degeneration (AMD) in patients taking glucagon-like peptide-1 receptor agonists (GLP-1RAs). From their Ophthalmology Retina article, "Glucagon-Like Peptide-1 Receptor Agonist Use and Risk of Neovascular Age-Related Macular Degeneration in a National Cohort Study."

Glucagon-Like Peptide-1 Receptor Agonist Use and Risk of Neovascular Age-Related Macular Degeneration in a National Cohort Study. Allan, Kevin C. et al. Ophthalmology Retina. In press

Sign up for the next Ophthalmology Journal Virtual Club on February 25, 2026, at https://store.aao.org/ophthalmology-virtual-journal-club.html

Dr. Edmund Tsui and author Dr. Douglas A. Jabs discuss the results of the ADVISE Trial, designed to compare adalimumab to conventional immunosuppressive drugs for the treatment of non-infectious intermediate, posterior, and panuveitides. From Dr. Jab's Ophthalmology article, "Adalimumab vs. Conventional Immunosuppression for Uveitis (ADVISE) Trial."

Adalimumab vs. Conventional Immunosuppression for Uveitis (ADVISE) Trial. Jabs, Douglas A. et al. Ophthalmology. In press.

Sign up for the next Ophthalmology Journal Virtual Club on February 25, 2026, at https://store.aao.org/ophthalmology-virtual-journal-club.html